Sareum Holdings PLC

Sareum Holdings PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)230.00
  • Today's Change2.50 / 1.10%
  • Shares traded57.31k
  • 1 Year change+73.58%
  • Beta-0.3187
Data delayed at least 20 minutes, as of May 20 2022 16:35 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Sareum Holdings plc is a United-Kingdom based holding company. It is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry, and medicinal chemistry. Its drug programs include Checkpoint Kinase 1 (Chk1), TYK2/JAK1 Autoimmune, TYK2/JAK1 Cancer and Aurora+FLT3 Kinase. The Checkpoint Kinase 1 (Chk1) inhibitor SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and central mediator of the DNA damage response (DDR) network. The TYK2/JAK1 are both members of the Janus kinase (JAK) family of protein kinase enzymes with important roles in maintaining a healthy immune system. Both kinases promote inflammatory responses in autoimmune diseases, respiratory infections and tumor cell proliferation in certain cancers. Aurora+FLT3 Kinase Programme targets Acute Myeloid Leukemia (AML) and other blood cancers.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-1.81m
  • Incorporated2004
  • Employees6.00
  • Location
    Sareum Holdings PLCUnit 2ALangford Arch, London Road, PampisfordCAMBRIDGE CB22 3FXUnited KingdomGBR
  • Phone+44 122 349 7700
  • Fax+44 122 349 7701
  • Websitehttp://www.sareum.co.uk/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Futura Medical plc.0.00-4.96m78.86m13.00--8.11-----0.018-0.0180.000.03390.00-------73.87-65.78-93.73-86.83-------6,607.25-------------105.85--123.78--
Eco Animal Health Group Plc101.55m5.57m82.96m207.0014.880.99235.850.81690.08230.08231.501.230.91312.173.60490,584.5011.3110.5515.4013.1449.9348.5312.3814.622.57--0.014547.1946.4617.51109.456.21-30.72-29.40
Science in Sport PLC62.54m-6.82m83.45m218.00--1.84--1.33-0.0505-0.05050.46290.32620.91384.055.55286,876.20-9.96-9.41-12.46-11.3050.1349.61-10.90-11.801.14-45.820.2197--24.2138.56-294.50--46.77--
e-Therapeutics plc477.00k-8.07m100.21m32.00--3.58--210.09-0.0169-0.01690.0010.05440.0217--3.3114,906.25-36.62-37.71-38.29-40.40100.00100.00-1,691.82-1,812.91----0.0239--50.47---119.06--42.31--
Scancell Holdings Plc0.00-8.41m100.88m25.00--4.45-----0.0105-0.01050.000.02780.00----0.00-21.98-48.49-24.78-52.14------------0.2598-------181.09------
Faron Pharmaceuticals Oy0.00-17.94m124.52m37.00--50.44-----0.3537-0.35370.000.04640.00----0.00-196.84-165.50-539.12-391.61-------487,178.90---248.330.5486-------25.16--38.80--
Circassia Group PLC27.90m2.30m153.89m128.0083.412.1122.635.520.00440.00750.0640.17420.29452.662.45217,968.802.43-11.692.80-13.9968.1076.198.24-81.991.58--0.0191--16.743.85108.58---22.16--
Sareum Holdings Plc0.00-1.81m156.56m6.00--27.57-----0.0273-0.02730.000.08340.00----0.00-48.39-49.67-51.44-54.40-------10,610.04----0.00---100.00---52.18------
Redx Pharma PLC10.04m-21.58m165.17m71.00--12.58--16.46-0.0855-0.08550.03910.04770.2769--2.46141,338.00-59.54-40.30-83.07-66.57-----215.01-85.78---11.630.5698--76.52---134.19--11.17--
Creo Medical Group PLC22.33m-21.16m173.96m245.00--2.96--7.79-0.1346-0.13460.14190.32440.27823.125.08102,891.70-26.37---31.21--45.54---94.79--2.17-53.680.1703--69,899.11---27.68------
Animalcare Group Plc74.02m-77.00k181.78m211.00--2.3121.842.46-0.0013-0.00131.231.310.63152.998.57350,824.70-0.0657---0.0768--53.25---0.104--0.96647.160.1221--5.01---132.91------
Bioventix PLC10.50m6.62m186.23m17.0028.4019.1427.5417.741.,437.1060.6552.3765.6955.5592.8392.3063.0865.2910.60123.630.0070.905.9814.65-6.5414.0165.4327.46
Data as of May 20 2022. Currency figures normalised to Sareum Holdings PLC's reporting currency: UK Pound GBX

Institutional shareholders

24.51%Per cent of shares held by top holders
HolderShares% Held
Hargreaves Lansdown Stockbrokers Ltd.as of 02 Jan 20227.54m11.08%
Hargreaves Lansdown Asset Management Ltd.as of 02 Jan 20224.09m6.01%
HSBC Global Asset Management (UK) Ltd.as of 02 Jan 20222.93m4.30%
Jarvis Investment Management Ltd.as of 02 Jan 2022744.34k1.09%
IG Markets Ltd.as of 02 Jan 2022423.30k0.62%
HSBC Bank Plc (Market-Maker)as of 02 Jan 2022403.66k0.59%
Tilney Investment Management Services Ltd.as of 02 Jan 2022182.34k0.27%
Rowan Dartington & Co. Ltd. (Broker)as of 02 Jan 2022170.20k0.25%
J. M. Finn & Co. Ltd.as of 02 Jan 202298.46k0.15%
KW Investment Management Ltd.as of 02 Jan 202295.80k0.14%
More ▼
Data from 30 Sep 2020 - 05 May 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.